Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Shiven B. Patel"'
Publikováno v:
Case Reports in Oncology, Vol 16, Iss 1, Pp 45-48 (2023)
Patients may present with multiple malignancies in the setting of particular environmental and occupational exposures. These patients often require combination systemic therapy, which has not yet been studied for concurrent use. While toxicities for
Externí odkaz:
https://doaj.org/article/6a6e14fc2f5f44a89ef56e2664ac666c
Publikováno v:
Case Reports in Oncology, Vol 12, Iss 3, Pp 866-871 (2019)
Adenosquamous carcinoma is a rare type of non-small cell lung cancer associated with advanced disease and poor prognosis. There is limited data for the management of mixed histology disease in elderly or frail patients. A 79-year-old woman with no sm
Externí odkaz:
https://doaj.org/article/323f43a2ac6e403bafc9a5ba5e7a4eb3
Autor:
Peter D. Stetson, Nadine J. McCleary, Travis Osterman, Kavitha Ramchandran, Amye Tevaarwerk, Tracy Wong, Jessica M. Sugalski, Wallace Akerley, Annette Mercurio, Finly J. Zachariah, Jonathan Yamzon, Robert C. Stillman, Peter E. Gabriel, Tricia Heinrichs, Kathleen Kerrigan, Shiven B. Patel, Scott M. Gilbert, Everett Weiss
Publikováno v:
Journal of the National Comprehensive Cancer Network. :1-6
Background: Collecting, monitoring, and responding to patient-generated health data (PGHD) are associated with improved quality of life and patient satisfaction, and possibly with improved patient survival in oncology. However, the current state of a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be50a3cd9cb04af7a4bd9938c10ef990
https://doi.org/10.6004/jnccn.2021.7088
https://doi.org/10.6004/jnccn.2021.7088
Autor:
Anna Weinberg Chalmers, Shiven B. Patel, K. Kerrigan, Neal J. Meropol, Tyler Haydell, Dominik Ose, Benjamin Haaland, Wallace Akerley
Publikováno v:
JCO Oncol Pract
PURPOSE: Performance status (PS), an established prognostic surrogate of cancer survival, is a physician-synthesized metric of patient symptoms and mobility that is prone to bias and subjectivity. The National Cancer Institute (NCI) Patient-Reported
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a61fbb97303f7beab3cefce658d9178
https://doi.org/10.1200/jop.19.00329
https://doi.org/10.1200/jop.19.00329
Autor:
Siwen Hu-Lieskovan, Kenneth F. Grossmann, Sarah Colonna, John R. Hyngstrom, Justin C. Moser, Shiven B. Patel, Jian Ying, Danli Chen
Publikováno v:
Cancer Medicine, Vol 8, Iss 18, Pp 7637-7643 (2019)
Cancer Medicine
Cancer Medicine
Background The optimal treatment sequence for patients with advanced BRAF V600 mutant melanoma is unknown. BRAF/MEK inhibition (BRAF/MEKi), single agent anti‐PD‐1 (aPD‐1) antibodies and combination immune checkpoint inhibition with nivolumab an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2a10872c2960d265961b648416224df
https://doaj.org/article/52b6fa49a3e44388aa94c0a04848fd13
https://doaj.org/article/52b6fa49a3e44388aa94c0a04848fd13
Publikováno v:
Case Reports in Oncology, Vol 12, Iss 3, Pp 866-871 (2019)
Adenosquamous carcinoma is a rare type of non-small cell lung cancer associated with advanced disease and poor prognosis. There is limited data for the management of mixed histology disease in elderly or frail patients. A 79-year-old woman with no sm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c7184da29f376b525c6b8b93d6a374c
https://www.karger.com/Article/FullText/504473
https://www.karger.com/Article/FullText/504473
Autor:
Natalie Graves, Kenneth M. Boucher, Terry Van Duren, Julie Luckart, Michelle Esplin, Laura Cannon, Wallace Akerley, Shiven B. Patel, Anna Weinberg Chalmers
Publikováno v:
Targeted Oncology. 14:417-421
The natural histories of, and treatment options for, epidermal growth factor receptor (EGFR)-mutated and anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancers (NSCLCs) are distinctly different from those of lung cancer that lacks ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79a55289a14f71b4d08fdfc0c2d0bddd
https://doi.org/10.1007/s11523-019-00658-0
https://doi.org/10.1007/s11523-019-00658-0
Publikováno v:
Journal of Oncology Pharmacy Practice. 26:224-227
Purpose Nivolumab is a fully human IgG4 programmed death 1 immune checkpoint inhibitor (ICI) antibody that has anti-tumor activity by selectively blocking the interaction of the programmed death 1 receptor with its two known programmed death ligands
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f155090289f72a52c19606d8c20f4b1
https://doi.org/10.1177/1078155219835912
https://doi.org/10.1177/1078155219835912
Autor:
Taofeek K. Owonikoko, Andrew Elliott, Bhakti Dwivedi, Andrey Ivanov, Gabriel Sica, Sonam Puri, Abdul Rafeh Naqash, Kathleen Claire Kerrigan, Shiven B. Patel, Andreas Seeber, Florian Kocher, Dipesh Uprety, Hirva Mamdani, Amit Kulkarni, Gilberto Lopes, Balazs Halmos, Wallace L. Akerley, Stephen V Liu, Wolfgang Michael Korn, Hossein Borghaei
Publikováno v:
Journal of Clinical Oncology. 40:8515-8515
8515 Background: Effective treatment options for SCLC remain limited and new treatment approaches are needed to improve outcome. We sought to validate the initial observation in cell lines and limited tissue samples of SCLC of a differential expressi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2987124be2fb1b881ccc64c8164666bb
https://doi.org/10.1200/jco.2022.40.16_suppl.8515
https://doi.org/10.1200/jco.2022.40.16_suppl.8515
Autor:
Joel W. Neal, Armando Santoro, Santiago Viteri, Santiago Ponce Aix, Bruno Fang, Farah Louise Lim, Ryan D. Gentzler, Jerome H. Goldschmidt, Polina Khrizman, Erminia Massarelli, Shiven B. Patel, Sonam Puri, Ramu Sudhagoni, Christian Scheffold, Dominic Curran, Enriqueta Felip
Publikováno v:
Journal of Clinical Oncology. 40:9005-9005
9005 Background: C, a multitargeted receptor tyrosine kinase inhibitor (TKI), promotes an immune-permissive environment that may enhance ICI activity. COSMIC-021 (NCT03170960) is a multicenter phase 1b study evaluating C + A in advanced solid tumors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4197c4935f2f6ea1e5e6fbc5c01cc72
https://doi.org/10.1200/jco.2022.40.16_suppl.9005
https://doi.org/10.1200/jco.2022.40.16_suppl.9005